This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a University of Alberta directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
- $1,204,876
Protease Targeted Therapeutics to Address the Global AMR Threat Associated with Pathogenic E. coli
CIHR · 2026 · Nominated PI
- $738,226
Assessing DGK Alpha as the Key Target for a Promising Immunomodulatory Compound: Mechanism and Implications in cancer immunotherapy
CIHR · 2025 · Co-investigator
- $860,625
Targeting SARS-CoV-2 Main protease and variants for effective antiviral development
CIHR · 2021 · Nominated PI
Protease Targeted Therapeutics to Address the Global AMR Threat Associated with Pathogenic E. coli
Principal investigators: Lemieux, Joanne M
Keywords: Bacterial Infections; Biofilm; Drug Development; Enzymology; Ibd; Pili; Protease; Proteolytic Inhibitor; Structural Biology; Uti
Assessing DGK Alpha as the Key Target for a Promising Immunomodulatory Compound: Mechanism and Implications in cancer immunotherapy
Principal investigators: Barakat, Khaled H
Keywords: Immunotherapy; Mode Of Action; Target Identification
Targeting SARS-CoV-2 Main protease and variants for effective antiviral development
Principal investigators: Lemieux, Joanne M
Keywords: Adme; Crystallography; Drug Discovery; Enzymology; Kinetics; Medicinal Chemistry; Protease; Sars-Cov-2; Variants; Virology
COVID-19 Variant Supplement - Optimizing polar, small inhibitors of a viral cysteine protease to identify a lead for an oral COVID-19 treatment
Principal investigators: Lemieux, Joanne M
Keywords: Antiviral Drugs; Co-Crystallization; Coronavirus; Covid-19; Cysteine Protease Inhibitor; Lead Identification; Molecular Modelling; Sars-Cov-2; Small Molecule Drug Discovery
COVID-19 Variant Network - Optimizing polar, small inhibitors of a viral cysteine protease to identify a lead for an oral COVID-19 treatment
Principal investigators: Lemieux, Joanne M
Keywords: Antiviral Drugs; Co-Crystallization; Coronavirus; Covid-19; Cysteine Protease Inhibitor; Lead Identification; Molecular Modelling; Sars-Cov-2; Small Molecule Drug Discovery
Investigating the cell-based activity of a new class of cytotoxic T-lymphocyte antigen-4 (CTLA-4) small molecule inhibitors
Principal investigators: Barakat, Khaled H
Keywords: Ctla-4; Immunological Response; Immunotherapy; Melanoma
Optimizing polar, small inhibitors of a viral cysteine protease to identify a lead for an oral COVID-19 treatment
Principal investigators: Lemieux, Joanne M
Keywords: Antiviral Drugs; Co-Crystallization; Coronavirus; Covid-19; Cysteine Protease Inhibitor; Lead Identification; Molecular Modelling; Sars-Cov-2; Small Molecule Drug Discovery
Synthesis, Structural Studies and Evaluation of Inhibitors of the 3CL Protease of SARS-CoV-2 as Potential Drugs for Treating Infection
Principal investigators: Lemieux, Joanne M
Keywords: Antiviral Drugs; Development And Evaluation Of Candidate Therapeutics; Drug Design And Delivery; Enzymology; Medical Countermeasures Research; Peptide Protein Interaction; Protein Crystallography; Protein Structure; Viral Protease; Virulence
Advancing a Potent Inhibitor of SARS-CoV-2 3CL Protease into Clinical Trials
Principal investigators: Tyrrell, D. Lorne J
Keywords: Animal Disease; Antiviral Therapy; Clinical Trial; Covid-19; Feline Infectious Peritonitis; Protease Inhibitor
10th International Proteolysis Society Meeting: Frontiers in Proteolysis
Principal investigators: Lemieux, Joanne M
Keywords: Biotechnology; Crystallography; Drug Discovery; Imagining; Kinetics; Protease; Proteolysis; Proteomics
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.